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Abstract Parkinson’s disease (PD) and Dementia with
Lewy bodies (DLB) are neurodegenerative diseases that
are characterized by intra-neuronal inclusions of Lewy
bodies in distinct brain regions. These inclusions consist
mainly of aggregated a-synuclein (a-syn) protein. The
present study used immunoprecipitation combined with
nanoﬂow liquid chromatography (LC) coupled to high
resolution electrospray ionization Fourier transform ion
cyclotron resonance tandem mass spectrometry (ESI-
FTICR-MS/MS) to determine known and novel isoforms of
a-syn in brain tissue homogenates. N-terminally acetylated
full-length a-syn (Ac-a-syn1–140) and two N-terminally
acetylated C-terminally truncated forms of a-syn (Ac-
a-syn1–139 and Ac-a-syn1–103) were found. The different
forms of a-syn were further studied by Western blotting in
brain tissue homogenates from the temporal cortex Brod-
mann area 36 (BA36) and the dorsolateral prefrontal cortex
BA9 derived from controls, patients with DLB and PD with
dementia (PDD). Quantiﬁcation of a-syn in each brain
tissue fraction was performed using a novel enzyme-linked
immunosorbent assay (ELISA).
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Introduction
a-Synuclein (a-syn) is a cytosolic protein, enriched in pre-
synaptic terminals associated with synaptic vesicles [1, 2].
Four known alternatively spliced isoforms of a-syn exist,
full-length that consist of 140 amino acids and shorter
isoforms of 126 (missing amino acids 41–54), 112 (missing
amino acids 103–130) and 98 (missing amino acids 41–54
and 103–130) amino acids, respectively [3, 4]. Besides a-,
b- and c-syn are members of the protein family of synu-
cleins. a- and b-syn proteins are primarily found in brain
tissue, while c-syn predominates in the peripheral nervous
system [5].
The ﬁrst indication of involvement of a-syn in the
pathogenesis of neurodegenerative diseases came from the
isolation of a short peptide (non-amyloid component,
NAC) derived from the amyloid plaques from the brains of
patients with Alzheimer’s disease (AD) [6]. Amino acid
sequencing revealed that this component consisted of a
35-amino acid-peptide, corresponding to residues 61–95 of
a-syn [6]. Subsequently, it was demonstrated that a-syn
was the major component of intracellular aggregates
present in Lewy bodies in Parkinson’s disease (PD) and
dementia with Lewy bodies (DLB) and in glial cytoplasmic
inclusions of multiple system atrophy [7–10]. These dis-
eases are collectively known as the ‘‘synucleinopathies’’.
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DOI 10.1007/s11064-011-0527-xSeveral studies have convincingly demonstrated clinical
and pathological similarities between DLB, PD and PD
with dementia (PDD), the distinctive feature being the
relative timing of dementia and Parkinsonism [11]. Find-
ings of missense mutations in the gene encoding a-syn
(SNCA)[ 12, 13] and multiplications of SNCA in families
with PD [14] promote the conversion of a-syn from soluble
monomers to aggregated, insoluble forms in the brain,
which is thought to be an important event in the patho-
genesis of synucleinopathies [15]. Moreover, different
post-translationally modiﬁed forms of a-syn have been
identiﬁed, including phosphorylated, nitrated, and ubiqui-
tinated a-syn [16–18]. Truncated forms of a-syn have been
isolated from Lewy bodies and several studies have also
shown that speciﬁc truncated forms of a-syn have enhanced
tendency to form aggregates [19]. This tendency of trun-
cated a-syn species to rapidly aggregate suggests that they
may play a role in inducing Lewy body formation.
In AD, distinct cerebrospinal ﬂuid (CSF) markers have
been developed and validated to complement the clinical
diagnosis [20]. For synucleinopathies, most assays are in
the early stages of development, but there are promising
preliminary results on CSF measurements of a-syn [21–24]
although no conclusive Lewy body-associated changes
have been found. This reminds of a similar situation in AD
research 20 years ago. The ﬁrst reports on CSF amyloid-
beta peptide (Ab) as a biomarker for AD were disap-
pointing, and results ranged from a slight decrease in AD to
no change. In these studies, total Ab in the CSF was
measured. After research showed that there are several
C-terminally truncated forms of Ab [25], and that one
speciﬁc isoform, the 42 amino acid long Ab peptide
(Ab1–42) is the most prone to form AD-associated senile
plaques, ELISA methods were developed with antibodies
speciﬁc for this form. Today, a combination of Ab1–42,
total-tau, and phospho-tau is used to identify incipient AD
with good sensitivity and speciﬁcity [26]. Presence of an
altered variant of a-syn that can reﬂect subtypes of PD can
therefore be anticipated.
The purpose of the study was to investigate and char-
acterize the variants of a-syn in post-mortem brains from
controls and patients with DLB and PDD. a-Syn from
human brain tissue was biochemically fractionated in
absence or presence of different detergents leading to
separation of a-syn according to solubility. We have in this
study applied a hybrid approach, where an afﬁnity based
puriﬁcation is combined with two different top-down mass
spectrometry approaches to analyze the selectively puriﬁed
endogenous peptides and proteins [27–30]. An immuno-
precipitation method was optimized to analyze a-syn in the
brain tissue homogenates by matrix-assisted laser desorp-
tion/ionization time-of-ﬂight MS (MALDI-TOFMS).
Using this immunoprecipitation method combined with
nanoﬂow liquid chromatography (LC) coupled to high
resolution electrospray ionization Fourier transform ion
cyclotron resonance tandem MS (ESI-FTICR-MS/MS) we
were able to detect and identify N-terminally acetylated
full-length a-syn (Ac-a-syn1–140) and two N-terminally
acetylated truncated forms of a-syn (Ac-a-syn1–139 and
Ac-a-syn1–103). The different forms of a-syn were further
studied by Western blot analysis in brain tissue homoge-
nates from the temporal cortex Brodmann area 36 (BA36)
and the dorsolateral prefrontal cortex BA9 derived from
controls, patients with DLB and PDD. Quantiﬁcation of
a-syn in each brain tissue fraction was performed using a
novel enzyme-linked immunosorbent assay (ELISA).
Experimental Procedure
Brain Tissue Samples
This study involves seven autopsy-conﬁrmed patients with
DLB (N = 3) or PDD (N = 4) and age-matched controls
(N = 6), from the Brains for Dementia Research (UK) and
StavangerBrainBankResources.Table 1showstheclinical
and demographic characteristics of the groups. All subjects
received prospective, standardized, annual clinical evalua-
tions during life, including clinical histories, cognitive and
motor evaluations. The clinical assessment battery incor-
porated successivecognitiveevaluationswhich includedthe
Mini-Mental State Examinination [31] and longitudinal
clinical assessment of Parkinsonism. The patients were
diagnosed clinically and neuropathologically according to
consensuscriteria[11,32,33].Controlswereselectedonthe
basis of the absence of psychiatric or neurological disease
and of no demonstrable neuropathological abnormality in
the brain. The clinical and autopsy aspects of the study were
fully approved by the appropriate Human Subject Research
Ethic Committee in Newcastle.
All neuropathologic evaluations were performed blind
to clinical assignment. Snap frozen blocks of tissue,
maintained at -70C from the temporal cortex Brodmann
area 36 (BA36) and dorsolateral prefrontal cortex BA9
were sub-dissected to remove white matter and receive
representative samples of grey matter. The severity of
plaques was assessed using the Consortium to Establish a
Registry for Alzheimer’s Disease (CERAD) guidelines
[34]. Braak and Braak staging was performed to stage
tangle pathology [35] and Lewy bodies were stained using
immunohistochemistry as described by Ballard et al. [36]
and assessed in brainstem, limbic and neocortical areas
using the principles outlined in the DLB consensus criteria
[32, 33]. In addition, a 0–20 semi-quantiﬁed scale was
completed following the same hierarchy as the system
within the DLB consensus criteria but incorporating
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123additional rating points with the neocortical range as pre-
viously described [32, 33, 36]. The scoring from 0 to 10
reﬂects brainstem and limbic cortex pathology, and scores
from 11 to 20 provide a semi-quantitative measure, with a
particular emphasis on neocortical pathology. Table 2
presents the results from the neuropathological staging.
Brain tissues (superior parietal gyrus) from patients with
AD were used for the optimization of the immunoprecip-
itation method of a-syn.
CSF Samples
The optimization of the immunoprecipitation method of
a-syn was also performed on decoded CSF samples from
the routine workﬂow at the Clinical Neurochemistry Lab-
oratory, Sahlgrenska University Hospital, from patients
who underwent lumbar puncture to exclude infectious
disorders of the central nervous system. No other clinical
data were available for these patients. Twelve milliliters
CSF was collected in a polypropylene tube and gently
mixed to avoid gradient effects. All samples were centri-
fuged at 2,000 g for 10 min to remove cells, and stored in
aliquots at -80C pending biochemical analysis. The
inclusion criteria were normal white cell count, normal
blood–brain barrier function and the absence of intrathecal
IgG and IgM production.
Homogenization of Brain Tissue
The brain extraction procedure was performed as described
by Deramecourt et al. with minor modiﬁcations [37].
Brieﬂy, 100–150 mg of brain tissue was homogenized on
Table 1 Clinical and demographic characteristics of the groups according to timing of dementia and Parkinsonism
Sample no Groups Regions Gender Age at
death (y)
Duration of PD
symptoms
at death (y)
Duration of
dementia
at death (y)
MMSE
closest
to death
6 DLB BA36/BA9 Male 92 9 9 12
7 PDD BA36/BA9 Male 81 10 6 6
8 PDD BA36/BA9 Male 79 19 8 22
9 DLB BA36/BA9 Male 63 8 9
10 DLB BA36 Female 69 10 10 19
18 PDD BA9 Male 75 4 2 17
20 PDD BA9 Male 77 12 2 *
4 Control BA36/BA9 Male 64
5 Control BA36 Male 87
1 Control BA36 Male 85
2 Control BA36 Female 85
3 Control BA36 Female 63
12 Control BA9 Female 82
Abbreviations used: BA Brodmann area, DLB dementia with Lewy bodies, MMSE Mini-mental state examination, PDD Parkinson’s disease with
dementia, y years
* No MMSE score, but other cognitive screening tests suggest dementia of moderate severity
Table 2 Results from the neuropathological tests
a
Sample no Groups Braak stage Plaques (CERAD) LB stage LB disease score
6 DLB 4 Moderate Neocortical 14
7 PDD 2 None Neocortical 11
8 PDD 4 Scarce Neocortical 20
9 DLB 6 Moderate Neocortical 10
10 DLB 2 Scarce Neocortical 11
18 PDD 3 Scarce Neocortical 19
20 PDD 3 Moderate Neocortical 16
a Please refer to Materials and methods for more information regarding these tests
Abbreviations used: CERAD Consortium to Establish a Registry for Alzheimer’s Disease, DLB dementia with Lewy bodies, LB Lewy body,
PDD Parkinson’s disease with dementia
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123ice in 1 mL Tris-buffer (10 mM Tris–HCl, pH 6.8) con-
taining complete protease inhibitor (Roche Diagnostics
GmBH). Centrifugation of the homogenate occurred at
31,000 g for 1 h at ?4C and the supernatant was collected
(Tris). One milliliter of Tris-buffer containing 0.5%
Triton
 X-100 (Union Carbide Corporation) was added to
the pellet homogenized on ice and sonicated using a micro-
probe sonicator. The centrifugation step was repeated and
the supernatant was collected (0.5% Triton
). The same
procedure was repeated by addition of Tris-buffer con-
taining 2% Triton
 (2% Triton
) and by addition of Tris-
buffer containing 0.5% sodium dodecyl sulphate (SDS) for
a ﬁnal centrifugation at ?12C (SDS). The ﬁnal pellets
were stored at -80C pending Western blot analysis.
Antibodies of Synucleins
The following antibodies were used; the monoclonal
Syn1b (3B5) recognized amino acids 113–126 (LED-
MPVDPDNEAYE), the monoclonal anti-a-syn antibody
Clone 42 (BD Transduction Laboratories) which was raised
against amino acids 15–123 of rat a-syn, and the rabbit
polyclonal a/b/c-syn antibody FL140 (Santa Cruz Biotech-
nology).Themonoclonalanti-a-synantibody Clone 42,also
called Syn-1 [16], was epitope-mapped using a series of
overlapping, linear peptides covering the C-terminal part of
the a-synuclein sequence. Its epitope was deﬁned as
A85GSIAAATGFFVVD98 using 14-mer N-terminally bio-
tinylated peptides overlapping with 7 amino acids.
Cloning and Puriﬁcation of Human a-syn
An a-syn open reading frame (from ATG to stop codon)
was ampliﬁed from a human brain cDNA library (HL5018;
Clontech) using primers based on published sequence data
(a-syn: accession number L08850), cloned in pGEM-T
cloning vector and completely conﬁrmed with sequencing.
The insert was subsequently sub-cloned in a PL-based
expression system (ICCG 3307; Innogenetics) adding six
additional histidines (His) at the amino-terminal. The His-
tagged syn fusion proteins were expressed in E. coli and
solubilized in 7 M guanidinium hydrochloride on a nickel
immobilized metal afﬁnity chromatography (Ni-IMAC).
The purity of the His-tagged a-syn preparation was
checked by SDS–PAGE and silverstaining and was
judged[98% pure. Protein concentration was determined
by amino acid composition analysis on separate aliquots.
Immunoprecipitation
The immunoprecipitation methods of brain tissue extracts
were developed using the instructions from the manufac-
turer’s product description (Invitrogen Corporation), and
using the KingFisher
 magnetic particle processor (Thermo
Fisher Scientiﬁc). Optimization of the immunoprecipitation
method was done for MALDI-TOFMS analyses of endog-
enous a-syn in brain tissue extracts and in most experiments
by addition of standard of a-syn (7.5 pmol) to phosphate-
buffered saline (PBS) (10 mM Na-phosphate, 0.15 M
NaCl, pH 7.4) and/or CSF samples. The following
parameters were tested; two different antibodies (mono-
clonal anti-a-syn antibody Clone 42 and monoclonal syn1b
antibody); the amount of antibodies (0.8 and 8 lg) boun-
ded to magnetic beads via anti-mouse IgG; volume of
beads (50 and 100 lL); presence/absence of n-octylg-
lucopyranoside (nOGP; 0.5 mM) (during incubation of
samples, elution of immunoprecipitated a-syn or prepara-
tion of eluted a-syn on the MALDI probe). Cross-linking of
antibodies to beads was investigated as well as the con-
centrations of Triton
 (0, 0.05, 0.5 and 2%) and SDS (0,
0.05 and 0.5%) in presence/absence of 0.025% Tween
 20
during the incubation of samples with antibody-bounded
beads. The ﬁnal method for immunoprecipitation of a-syn
is given below.
An aliquot (0.8 lg) of the monoclonal anti-a-syn anti-
bodyClone42(250 ng/L)orIgGfrommurineserum(1 g/L,
Sigma–Aldrich) (a negative control), was separately added
to 100 lL magnetic Dynabeads
 M-280 Sheep anti-mouse
IgG(InvitrogenCorporation)andincubated1 honarocking
platform at room temperature. The beads were washed three
times with 1 mL of PBS. The antibodies were cross-linked
using 20 mM dimethyl pimelimidate dihydrochloride
(DMP; Sigma–Aldrich) and 0.2 M triethanolamine (pH 8.2;
Sigma–Aldrich) according to the manufacturer’s product
description. Each brain tissue extract were adjusted with
10%Triton
andTristoaﬁnalconcentrationof2%Triton
.
The cross-linked beads were washed 3 times in 0.1% bovine
serum albumin (BSA) in PBS and added to the diluted brain
tissue extracts. Samples and magnetic beads were incubated
over night on a rocking platform at ?4C.
The magnetic beads/sample solution was transferred to
the KingFisher
 magnetic particle processor, tube 1. The
following three wash steps (tubes 2–4) were conducted for
10 s in 1 mL of each washing buffer: (tube 2) 0.025%
Tween
 20 in PBS, (tube 3) PBS and (tube 4) 50 mM
ammonium hydrogen carbonate (NH4HCO3, pH 8.0).
Then, a-syn was eluted from the beads by adding 100 lL
0.5 mM nOGP in 0.5% formic acid (FA) (tube 5) for
4 min. The eluted fractions were transferred to 0.5 mL
Protein LoBind Tube (Eppendorf AG) and dried in a vac-
uum centrifuge.
MALDI-TOFMS
MALDI-TOFMS measurements were performed using an
AUTOFLEX instrument (Bruker Daltonics) operating in
2032 Neurochem Res (2011) 36:2029–2042
123linear mode at 19 kV acceleration voltage. Each spectrum
represents an average of 1,500 shots acquired 50 at a time.
The MALDI samples were prepared with the seed layer
method as described previously with a-cyano-4-hydroxy-
cinnamic acid (CHCA) used as matrix [38]. All reported
mass-to-charge ratios (m/z) are the average peak of the
protonated molecule [M ? H]
?.
Nanoﬂow LC–ESI–MS
For the intact proteins in the top-down proteomics analysis
the brain homogenate fractions were subjected to two
consecutive immunoprecipitations with a-syn antibody to
decrease the chemical background. Subsequently, the dried
samples were dissolved in 25 lL of 20% acetonitrile
(ACN) in 0.1% formic acid (FA) for 1 h and then centri-
fuged (16,900 g, 10 min, ?4C) to eliminate particles. The
nanoﬂow LC-ESI-FTICR-MS/MS spectra were acquired
using an LTQ-FT classic (Thermo Fischer Scientiﬁc), a
hybrid linear ion trap–FTICR mass spectrometer equipped
with a 7 T magnet coupled to an Ettan MDLC (GE
Healthcare) multi-dimensional nanoﬂow chromatography
system. A HotSep Tracy C4 trap column (length 5 mm, i.d.
0.3 mm, particle size 5 lm (G&T Septech)) was used for
online desalting and sample clean-up, followed by a
nanoscale reversed phase HotSep Kromasil C4 column
(length 150 mm, i.d. 0.075 mm, particle size 5 lm (G&T
Septech)). Mobile phases were 0.1% aqueous FA (v/v)
(A) and 0.1% FA in 84% ACN in water (v/v) (B). The
separation was performed at a ﬂow rate of approximately
400 nL/min by applying a linear gradient of 0–60% B for
50 min. The LTQ-FT was operated in the data-dependent
mode, where a typical scan cycle consisted of one full scan
mass spectrum (m/z 600–1,500), a single ion monitoring
(SIM) scan and two tandem mass spectrometry (MS/MS)
scans using collision-induced dissociation (CID). All full
mass spectra and the ﬁrst MS/MS scan were acquired in
FTICR mode while the second MS/MS scan was acquired
in linear quadrupole ion trap (LQIT) mode. MS/MS iso-
lation width was set to 10 m/z units, and the normalized
collision energy to 35. Each scan consisted of three
microscans; full scans and SIM scans were acquired at the
resolution setting 100,000, while FTICR MS/MS scans
were acquired at 50,000.
Mono isotopic mass determination of both intact ions
and fragment ions was generated by the Xtract program in
the Xcalibur software (Thermo Fisher Scientiﬁc). In-house
developed software (Sequence v. 2.0) was then utilized to
match obtained peak lists to theoretical peptide mass lists.
Obtained ion fragment masses were compared with theo-
retical fragment masses with the aid of the Protein Calcu-
lator tool in the Xcalibur software. Database searches were
submitted to the in-house database server by using Mascot
Deamon 2.2 (Matrix Science) in combination with Mascot
Distiller v. 2.3.2.0 (Matrix Science). Database search
parameters were; database (Swissprot 57.15), taxonomy
(Homo sapiens), enzyme (none), variable modiﬁcations
(acetyl [N-term] and oxidation [M]), ﬁxed modiﬁcations
(none), mass values (monoisotopic), peptide mass tolerance
(20 ppm), fragment mass tolerance (100 mmu), and max
missed cleavages (not applicable).
In the bottom-up analysis of the in gel digested peptides
eluted from the 1D gels the dried samples were dissolved in
20 lL 0.1% FA, centrifuged and analyzed by a LTQ-FT
ultra coupled to an Ettan MDLC. Here a Zorbax 300
SB-C18 trap column (length 5 mm, inner diameter
0.3 mm, particle size 5 mm (Agilent Technologies)) was
used for on-line desalting and a reversed phase Zorbax 300
SBC18 column (length 150 mm, inner diameter 0.075 mm,
particle size 3.5 mm (Agilent Technologies)) was used for
high-resolution separation. The separation was performed
at a ﬂow rate of approximately 250 nL/min by applying the
same gradient and mobile phases as in the top-down
experiment. The LTQ-FT ultra was set to acquire positive
ions and operated in the data-dependent mode, where a
scan cycle consisted of one full scan mass spectrum
(m/z 350–1500) acquired in the FTICR mode, followed by
MS/MS scans of the ten most intense ions acquired in the
linear ion trap. Mascot Distiller v. 2.3.2.0 was used for
database search and protein identiﬁcation. Speciﬁed search
parameters were database (NCBInr 20100306), taxonomy
(Mammalia), enzyme (trypsin), variable modiﬁcations
(acetyl [N-term] and oxidation [M]), ﬁxed modiﬁcations
(carbamidomethyl [C]), mass values (monoisotopic), pep-
tide mass tolerance (10 ppm), fragment mass tolerance
(0.5 Da), and max missed cleavages (1). Only peptides
with individual ion scores[36 (indicating identity or
extensive homology (P\0.05)) were considered for
identiﬁcation.
Gel Electrophoresis and in-Gel Digestion
Dried immunoprecipitated brain homogenate fractions
(Tris, Triton
, and SDS) were dissolved in 15 uL
NuPAGE
 sample buffer. The samples were electropho-
resed using NuPAGE
 10% Bis–Tris gels (Invitrogen
Corporation) on NuPAGE mini gel system (Xcell II Mini-
Cell; Novex). Each fraction (lane) was sliced into 15
equally large pieces and washed twice with 100% ACN for
10 min each. ACN was replaced with 25 mM NH4HCO3
containing 10 mM dithiothreitol and incubated in ?56C
for 30 min. After removing the solution the gel pieces were
washed with ACN, replaced with 25 mM NH4HCO3 con-
taining 55 mM iodoacetamide (IAA) and incubated 20 min
in darkness at room temperature. After removing the
solution the gel pieces were washed with 50 mM
Neurochem Res (2011) 36:2029–2042 2033
123NH4HCO3 for 10 min before removing the solution. The
gel pieces were then incubated for 5 min in ACN three
times before digestion with 12.5 ng/lL trypsin (Promega
Corporation) in 25 mM NH4HCO3 at ?37C overnight.
The supernatants were collected in cycles in new 0.5 mL
Protein LoBind Tubes. Gel pieces were then incubated for
10 min at room temperature in 25 mM NH4HCO3 and the
supernatants were then pooled with the previously col-
lected supernatants. The remaining peptides were extracted
by incubating the gel pieces for 15 min at ?37C in ACN,
5% FA and ACN, subsequently. After each incubation, the
supernatant was collected and pooled with the supernatants
previously collected. The pooled supernatants were dried
with vacuum centrifugation overnight and stored at -80C.
Dried peptides were dissolved in 20 lL 0.1% FA prior to
LC–ESI–MS/MS analysis.
Western Blotting
For protein quantitation, Protein DC assay (Bio-Rad Labo-
ratories)reagentwasused.Thisreagentisreducingagentand
detergent compatible. Aliquots of 5 lg (Tris and Triton
)
and10 lg(SDS)oftotalproteinweremixedwithNuPAGE

sample buffer. Pellets were dissolved in NuPAGE
 sample
buffer containing 5% litium dodecyl sulphate (LDS). All
samples were electrophoresed on NuPAGE
 10% Bis–Tris
gel using the NuPage
 mini-gel system. The proteins were
transferred to Immobilon
TM
-P PVDF membranes (Millipore
Corporation) using the semi-dry blotting technique.
Blocking was performed for 1 h at room temperature using
Roti
-Block (Carl Roth). Incubations with the monoclonal
anti-a-syn antibody Clone 42 (250 ng/L) diluted 1:1,000 in
Roti
-Block or no primary antibody (negative control) were
performedovernightat?4C.Themembranes were washed
for30,15,and2 9 10 mininPBS-T(0.05%v/vTween
20)
and then incubated for 1 h at room temperature with bio-
tinylated anti-mouse IgG antibody (Vector Laboratories)
(1 mg/mL),diluted1:3,000inPBS-T.AsecondPBS-Twash
was performed for 3 9 10 min after which the membranes
were incubated for 1 h at room temperature with streptavi-
din-biotinylated horseradish peroxidase complex (GE
Healthcare) diluted 1:3,000 in PBS-T. Following 3 9
10 min washes, the membranes were developed for 2 min
with ECL Advanced (GE Healthcare) solution according to
the manufacturer’s instructions. The emitted signal was
detected by a Fujiﬁlm LAS-3000 System (FUJIFILM Cor-
poration)andevaluatedusingtheMultiGaugev2.2software
(FUJIFILM Corporation). a-Syn band intensities (?(weak),
??(moderate), ???(strong)) were based on the optical
density of each band subtracting the background. All sam-
ples were analyzed in duplicate on two separate gels.
Sandwich ELISA Method for a-syn
A combination of rabbit polyclonal a/b/c-syn antibody
FL140, as capturing antibody, and the monoclonal anti-
body Syn1b, as detection antibody, resulted in the most
sensitive detection of a-syn in human brain tissue extract.
Maxisorp plates (Nunc) were coated with 100 lLo f
polyclonal FL140 antibody (200 ng/L), diluted 1:500 in
50 mM carbonate buffer, pH 9.6, and incubated over night
at ?4C. The plates were washed four times with 300 lL
of PBS and were blocked with 250 lL of 1% BSA in PBS
for 1 h at room temperature. The plates were washed
further four times with 300 lL of 0.1% BSA in PBS. The
washing procedure was repeated between every following
incubation step. All samples were analyzed in duplicate.
All brain tissue extracts were diluted 1:20 in 0.1% BSA,
1% Triton
 in PBS. The standard of a-syn was diluted in
0.1% BSA, 1% Triton
 in PBS to a concentration range of
0.39–50 lg/L. Samples (100 lL) of diluted brain tissue
extract and standard were incubated for 2 h at room tem-
perature. Then, 100 lL of monoclonal Syn1b antibody
(1.9 g/L) diluted 1:2,000 in 0.1% BSA, 1% Triton
 in PBS
was incubated for 1 h at ?37C. Thereafter, 100 lLo f
mouse IgG-biotin (Sigma–Aldrich) diluted 1:6,000 in 0.1%
BSA in PBS was added and incubated for 1 h at ?37C.
Then, NeutrAvidin Horseradish Peroxidase Conjugate
(1 g/L) (Thermo Scientiﬁc) diluted 1:5,000 in 1% Triton

in PBS was incubated for 1 h at room temperature, and
development occurred by adding 100 lL of 3,30,5,50-
tetramethylbenzidine substrate (TMB Peroxidase EIA
Substrate Kit; Bio-Rad Laboratories). The reaction was
quenched with 100 lLo fH 2SO4 (2 M). The absorbance
was measured at 450 nm. The concentration of a-syn in
samples of brain tissue extracts was calculated from the
standard curve. For each sample a ratio was calculated
where the a-syn level was divided by the total protein
concentration.
Statistical Analysis
All statistical analyses were performed using the Statistical
Package of the Social Science (SPSS). Data are given as
median (inter-quartile range). The Mann–Whitney test was
used to investigate group differences.
Ethics
The study was conducted in accordance with the provisions
of the Helsinki declaration and approved by the regional
ethics committees.
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Identiﬁcation of Novel Fragments of a-syn with Mass
Spectrometry
a-Syn was biochemically fractionated according to solu-
bility using non-ionic and ionic detergents at different
concentrations. Generally, the Tris fractions contain highly
soluble proteins (mainly cytosolic proteins), while mem-
brane-bound proteins are found in the Triton
 fractions.
The SDS fractions might represent raft-associated a-syn
[37, 39]. Triton
 at a higher concentration (2%) was
applied to ensure extraction of all membrane-bound a-syn.
Optimization of the immunoprecipitation method was done
for MALDI-TOFMS analyses of endogenous a-syn in brain
tissue extracts and in most experiments by addition of
standard of a-syn to PBS and/or CSF samples. Subse-
quently, the optimized MALDI-TOFMS settings and
sample preparation protocol were utilized to acquire mass
spectra of the immunoprecipitated brain homogenate
fractions. Even though the immunoprecipitation greatly
reduced the complexity of the original brain homogenate
samples, unspeciﬁc binding still occurred. However, by
comparing the mass spectra from the samples immuno-
precipitated with the a-syn antibody and the respective
negative controls, several peaks/compounds that were
speciﬁc for a-syn immunoprecipitation could be distin-
guished (Fig. 1). The most prominent features in the
MALDI mass spectra that were speciﬁc for the a-syn
immunoprecipitated samples were two peaks detected at
m/z 14,505 and m/z 7,250 (not shown), respectively (Fig. 1
b, d, f). These experimental m/z values agree with the
theoretical m/z of the singly and doubly protonated full-
length N-terminally acetylated a-syn (Ac-a-syn1–140)( m / z
14,503 and m/z 7,252 with average mass values) within the
speciﬁed mass accuracy of the method. Several other peaks
could only be detected in the samples immunoprecipitated
with the a-syn antibody but limited mass accuracy of the
MALDI-TOFMS made it difﬁcult to interpret in silico
searches of potential truncated forms of a-syn.
To obtain accurate mass values of the tentative a-syn
species and if possible verify their identity with amino acid
sequence information, we developed an online top-down
proteomics approach where LC–ESI–MS/MS analysis of
the immunoprecipitated brain homogenate fractions was
utilized. The major strength of the top-down approach is
that a discrepancy between the measured molecular mass
and that predicted by the DNA sequence directly reveals
the presence of modiﬁcations, sequence errors, or variants.
Furthermore, tandem mass spectrometric analysis of the
intact fully modiﬁed protein can verify the identity and
determine the locations of the modiﬁcations or sequence
variants. However, in general MALDI-MS has shown a
greater ability to detect proteins in complex mixtures in the
presence of high concentrations of salts, buffers, deter-
gents, and other species than ESI–MS. Unless the sample is
relatively pure the ESI–MS technique requires a clean-up
procedure prior to injection. This is typically accomplished
by coupling one or more separation/puriﬁcation step, e.g.,
LC, on- or ofﬂine to the ESI-source. Because of the high
complexity of the samples investigated in this study, we
found that it was beneﬁciary to add a second immunopre-
cipitation as a further cleaning step before the topdown
LC–ESI–MS/MS analysis in order to reduce the levels of
compounds that have bound non-speciﬁcally to beads and/
or antibodies. With this set-up Ac-a-syn1–140 was detected
with high mass accuracy in all three brain homogenate
fractions and veriﬁed with amino acid sequence data
(Fig. 2a–c, f, and Table 3). It is interesting to note that the
sequence tags conﬁrmed by the MS/MS data are speciﬁc
for a-syn and are not present in b-o ra-synuclein. Apart
from Ac-a-syn1–140 two novel truncated forms of a-syn
were tentatively identiﬁed. In both the Tris and Triton

fractions a fragment corresponding to N-terminally acety-
lated a-syn 1–103 (Ac-a-syn1–103) was detected and veri-
ﬁed with amino acid sequence data (Fig. 2d, e, and
Table 3). The identity of the Ac-a-syn1–103 form was also
independently conﬁrmed with a database search using mascot
distiller (Table 3). A peak with the corresponding m/z of
Ac-a-syn1–103 c a na l s ob ed i s c e r n e di nt h eM A L D I - T O F M S
spectra of the Triton
 brain homogenate fraction (Fig. 1d).
The other novel a-syn species that was detected with a
high mass accuracy and tentatively veriﬁed by partial top-
down amino acid sequence data during the LC–ESI–MS/
MS analysis was Ac-a-syn1–139 (Fig. 2a, b and Table 3).
Since Ac-a-syn1–139 and Ac-a-syn1–140 co-elute and
have similar m/z it was difﬁcult to speciﬁcally isolate
Ac-a-syn1–139 from Ac-a-syn1–140. The presented frag-
ment ion data was obtained in the analysis of the Tris
fraction. Even though this truncated a-syn form only differs
from the full length a-syn with one amino acid (ala-
nine), a tendency of a shift in relative concentration of
Ac-a-syn1–139 and Ac-a-syn1–140 between the Tris and the
Triton
 fractions (Fig. 2a, b), suggests that Ac-a-syn1–139
is somewhat more soluble than full-length a-syn. More-
over, an MS peak with approximately the mass value of
Ac-a-syn1–139 could be discerned in the MALDI-TOFMS
analysis, but the resolution of the method was too low
to fully resolve Ac-a-syn1–139 and Ac-a-syn1–140. The
MALDI-TOFMS data also showed a tendency to a more
intense Ac-a-syn1–139 peak compared to the Ac-a-syn1–140
peak in the analysis of the Tris fraction compared to the
Triton
 fraction.
A weak signal from one more tentative truncated form
of N-terminally acetylated a-syn (Ac-a-syn1–119), was
detected in the Triton
 brain homogenate fraction, but
Neurochem Res (2011) 36:2029–2042 2035
123unfortunately the identity could not be conﬁrmed with
tandem MS data (data not shown).
In addition, the proteins in the a-syn antibody immuno-
precipitated brain homogenate fractions were separated by
one-dimensional gel electrophoresis, subjected to in-gel
digestion with trypsin and analyzed by LC–ESI–MS/MS
(Table 4). The results conﬁrmed the presence of a-syn in
the brain homogenates, but despite up to 50% amino acid
sequence coverage neither the N-terminal nor the C-termi-
nal part of the amino acid sequence were identiﬁed in the
data base search. Generally, the highest concentration of
a-syn was detected at the gel bands containing proteins of
the approximate weight of *16 kDa for all three brain
homogenate fractions. Furthermore, the data indicated that
the Tris fraction contained higher molecular weight forms
of a-syn, possibly aggregates, and both the Tris and Triton

brain homogenate fractions contained lower molecular
weight (maybe truncated) a-syn forms. The truncated
a-syn forms at least contained amino acids 81–96.
Evaluation of a-syn by Western Blotting
The presence of full-length a-syn detected at *16 kDa
was also shown by Western blotting in all of the brain
homogenate fractions (Tris, Triton
, SDS) in both brain
regions—temporal cortex BA36 (Fig. 3a) and dorsolateral
prefrontal cortex BA9 (data not shown). In agreement
with previous studies, there were higher contents of full-
length a-syn in the Tris fractions and 0.5% Triton

fractions, respectively, than in the SDS fractions (data not
shown). In temporal cortex BA36, but not in dorsolateral
prefrontal cortex BA9, weak additional a-syn bands
of *12 kDa were observed in most of the Tris and
Triton
-soluble fractions from both controls and patients
with DLB and PDD (data not shown). Overall, there was
no visible difference in the content of either full-length or
truncated 12 kDa a-syn for the controls, the patients of
DLB and PDD in any of the brain homogenate fractions
(Tris, Triton
 or SDS) (data not shown). However, the
Western blotting of the pellet fractions from temporal
cortex BA36, clearly demonstrated that brains from
patients with DLB and PDD compared with control brains
had a considerably higher content of full-length a-syn
(Fig. 3c). Moreover, most pellets from patients with DLB
and PDD in temporal cortex BA36 contained additional
bands of 32, 12 and 8 kDa, which were absent in all
samples from controls (Fig. 3c). In contrast, in dorsolat-
eral prefrontal cortex BA9, there was no difference in the
relative content of full-length a-syn between controls and
patients with DLB and PDD, and the bands of *32, *12
and *8 kDa were only present in a few samples
(Fig. 3e).
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Fig. 1 MALDI TOF mass spectra of the brain homogenate fractions
(Tris fractions (a, b), Triton
 fractions (c, d), SDS fractions (e, f))
immunoprecipitated using the monoclonal anti-a-syn antibody Clone
42 (BD Transduction Laboratories) (b, d, f) or IgG from murine
serum (negative controls)( a, c, e)
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The intra-assay variation was determined by ten measure-
ments of two samples of brain tissue homogenate from
each fraction (Tris, 0.5% Triton
, SDS), which resulted in
a CV of 9.3% (N = 6). All samples from the study of
patients were analyzed at the same day. In agreement with
the Western blotting analysis, the ratios (a-syn/total
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Fig. 2 Nanoﬂow LC-ESI-FTICR full scan mass spectra showing the
a-syn forms Ac-a-syn1–139 (a, b) and Ac-a-syn1–140 (a–c). Note also
the presence of mono- and dioxidized forms. The spectra are summed
over a 1.5 min retention time interval around 46 min (50 min
gradient). In the spectra the 15 ? charge state of the Ac-a-syn1–139
and Ac-a-syn1–140 forms are indicated. One SIM scan (3 microscans)
of the 15 ? ion of the Ac-a-syn1–103 form (d, e). Spectra from the
LC–ESI–MS analysis of the Tris fraction of the brain homogenate
(a and d). Spectra from the LC–ESI–MS analysis of the Triton

fraction of the brain homogenate (b and e). Spectra from the LC–ESI–
MS analysis of the SDS fraction of the brain homogenate (c). The
detected y and b fragments are indicated in the respective sequences
(f). Cleavage sites labeled with bold lines are conﬁrmed by database
search
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123protein) were signiﬁcantly increased in the Tris fractions
(90 (77–124) (\0.001) (temporal cortex BA36) (N = 10)
and 61 (59–70) (P\0.001) (dorsolateral prefrontal cortex
BA9) (N = 8)) and Triton
 fractions (45 (41–60)
(P\0.001) (temporal cortex BA36) (N = 10) and 41
(36–46) (P\0.001) (dorsolateral prefrontal cortex BA9)
(N = 8)) compared with the SDS fractions (7 (6–8) (tem-
poral cortex BA36) (N = 10) and 4 (4–5) (dorsolateral
prefrontal cortex BA9) (N = 8)) (Fig. 4). The ratios
(a-syn/total protein) were signiﬁcantly increased in tem-
poral cortex BA36 compared with dorsolateral prefrontal
cortex BA9 for the Tris (P\0.05) and SDS (P\0.01)
fractions (see above) (Fig. 4), which also is consistent with
the Western blotting analyses. Fig. 4 shows each ratio
(a-syn/total protein) for controls and patients with DLB
and PDD within each brain region. Unfortunately, the
sample size was too low for assessing differences between
controls, patients with DLB and PDD (Fig. 4).
Discussion
Gene mutations of a-syn in familial PD [12, 13] and the
presence of aggregated a-syn protein in Lewy bodies
strongly suggest that a-syn plays a key role in the patho-
genesis of PD and DLB. The alteration of solubility of
a-syn, aggregating into Lewy bodies, might be relevant for
understanding the underlying pathogenic mechanism, and
tentatively facilitate earlier diagnosis and the development
of novel mechanism-based therapeutic interventions [40].
To our knowledge this is the ﬁrst study where intact a-syn
from human brain tissue has been characterized with mass
spectrometry. All four a-syn forms detected were N-ter-
minally acetylated. This is in agreement with data pre-
sented by Anderson et al. [16] and it is also commonly
known that N-terminal acetylation of cytosolic proteins,
especially in proteins initiated with a Met residue often
occurs [41] and has been shown in yeast to be indispens-
able for the proper plasma membrane targeting of a-syn
[42].
An especially interesting ﬁnding was the identiﬁcation
of the novel truncated a-syn Ac-a-syn1–103. This a-syn
species could tentatively be identical to the truncated form
observed both in this and previous studies with Western
blotting from the temporal cortex [43, 44]. In addition, the
weak a-syn band of *12 kDa was observed in most of the
Tris and Triton
-soluble fractions, but not in the SDS-
soluble fractions, which is in agreement with the mass
Table 3 a-syn forms detected by LC-ESI-FTICR-MS/MS
a-syn isoforms Theoretical
mass [Da]
a
Mass deviation
(ppm)
Fragments
detected (b/y)
Ac-a-syn1–140 14,493.23 2 15/3
Ac-a-syn1–139 14,422.19 5 2/0
Ac-a-syn1–103 10,339.56 4 8/7
a monoisotopic mass values
Table 4 Detection of a-syn
(NACP/alpha-synuclein NCBI
Accesion key gi
|1230575) in
different brain homogenate
fractions (Tris, Triton
, SDS)
separated by one-dimensional
gel electrophoresis combined
with MS/MS for protein
identiﬁcation
Fraction Approx.
MW
[kDa]
Sequence
coverage
[%]
Amino acids Unique
peptides
Tris 40 11 81–96 1
30 11 81–96 1
25 11 81–96 1
20 35 46–58, 61–96 3
16 50 11–21, 33–43, 46–58, 61–96 7
12 50 11–21,33–43,46–58,61–96 10
10 44 11–21, 44–58, 61–96 8
6 36 46–96 4
4 11 81–96 1
Triton
 20 11 81–96 1
16 49 11–21, 35–43, 46–58, 61–96 11
12 37 11–21, 33–58, 81–96 10
10 35 46–58, 61–96 5
6 20 46–58, 81–96 2
4 11 81–96 1
3 11 81–96 1
SDS 25 11 81–96 1
14 52 11–21,33–58,61–97 19
10 20 46–58, 81–96 3
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123spectrometry analysis. The *12 kDa band was only visi-
ble in brain homogenate fractions from the temporal cortex
region BA36 and not from the dorsolateral prefrontal cor-
tex. However, there were no differences in the content of
either full-length or truncated 12 kDa a-syn between the
controls and the patients of DLB/PDD in any of the brain
homogenate fractions, which is consistent with previous
studies [43, 45]. Recently, it was shown that matrix
metalloproteinase 3 (MMP-3) cleaves a-syn at Asp103 in
vitro [46]. Levin et al. have also shown that limited pro-
teolysis of a-syn by MMP-3 and MMP-1 leads to fragments
that increase aggregation of a-syn in vitro. The presence of
the Ac-a-syn1–103 form in the brain homogenate opens up
several interesting lines of investigation. One would be to
examine if Ac-a-syn1–103 is generated by MMP-3 cleavage
of a-syn in vivo. Another would be to compare the amount
of Ac-a-syn1–103 found in different brain samples from
controls and patients with DLB and PDD.
Tentative, but not conclusive evidence of one of the
truncated a-syn forms (Ac-a-syn1–119) that Anderson et al.
detected in Lewy bodies from patients with DLB was
found in this study [16]. However, we could not ﬁnd evi-
dence of the phosphorylated (P-S129) a-syn form or the
ubiquitinated phosphorylated a-syn discovered in the same
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6.5
14.4
21.5
31
1 23456789 10 11
(c)  Pellet fractions, BA36
6.5
14.4
31
123
(d)
21.5
kDa
k D a12 34 5 678 9
(a)  Tris, Triton and SDS fractions, BA36
kDa 12 3 45678 9
(b)  
6.5
14.4
21.5
31
6.5
14.4
21.5
31
kDa 1 2 3 4 5 6 7 8 9
(e)  Pellet fractions, BA9
k D a 123
(f)
6.5
14.4
21.5
31
6.5
14.4
21.5
31
α-syn (kDa) 23456789
32 + ++ +
16 + + + + + ++ + +
12
8
α-syn (kDa) 23456789 1 0 1 1
32 ++ +++ + +
16 + ++ +++ + ++ + +++ + +
12 + + +
8+ + + + +
Fig. 3 Western blotting of
biochemically fractionated
temporal cortex Brodmann area
36 (BA36) (a–d) and
dorsolateral prefrontal cortex
BA9 (e, f) from controls,
patients with dementia with
Lewy bodies (DLB) and
Parkinson’s disease with
dementia (PDD) using the
monoclonal anti-a-syn antibody
Clone 42 (a, c, e) and without
primary antibody (b, d, f).
Molecular markers (lane 1), Tris
fraction (lane 2 and 6), 0.5%
Triton
 fraction (lane 3 and 7),
2% Triton
 fraction (lane 4 and
8) and 0.5% SDS fraction (lane
5 and 9) from a control and
patient with DLB, respectively
(a, b). Western blotting of the
ﬁnal pellet (c–f) using the
monoclonal anti-a-syn antibody
Clone 42 (c, e) and without
primary antibody (d, f).
Molecular markers (lane 1),
from controls (lane 2, 4, 6, 8
and 10), patients with DLB
(lane 3, 9, 11) and PDD (lane 5,
7)( c). Molecular markers (lane
1), from controls (lane 2 and 4),
patients with DLB (lane 3) and
PDD (lane 5–9) (e). Molecular
markers (lane 1), from a control
(lane 2) and from a patient with
DLB (lane 3) (d, f). The table
below each Western blot
(c, e) shows the abundance of
the a-syn bands of 32, 16, 12,
and 8 kDa given. The intensities
of the band (?(weak),
??(moderate), ???(strong))
presented in the table panel are
based on optical density for
each band of a-syn subtracting
the background. Empty boxes
meaning no visible bands
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123study. Since both the examined material and the utilized
methods differ between this study and the study by
Anderson et al. it is difﬁcult to speculate on the reason
behind the discrepancies. One major difference between
the present study and Anderson et al. is that we have
focused mainly on the more soluble forms of a-syn while
they have concentrated on the least soluble forms.
Previousstudieshaveshownthata-synisahighlysoluble
protein mainly localized in the cytosol and enriched in pre-
synaptic terminals where it might be organized in lipid rafts
and in association with synaptic vesicles [1, 2, 39, 47]. In
accordance with those studies, ELISA analyses of the brain
homogenate fractions showed that the ratios (a-syn/total
protein) were signiﬁcantly increased in the Tris fractions
(solublea-syn),andtheTriton
fractions(membrane-bound
a-syn) compared with the SDS fractions (raft associated
a-syn). This ﬁnding was conﬁrmed by the Western blot
analyses of full-length a-syn. In addition, our data indicate
that a-syn is differently expressed in brain regions, since the
ratios (a-syn/total protein) were signiﬁcantly increased in
temporal cortex BA36 compared with dorsolateral pre-
frontal cortex BA9 for the fractions of Tris and SDS, which
also is consistent with the Western blotting analyses.
Interestingly, we found that the pellet fractions, which
contain the remaining aggregates of a-syn, from brain
region temporal cortex from patients with DLB and PDD,
had a considerable higher content of full-length a-syn
(16 kDa) and also contained additional a-syn bands of
32 kDa (probably dimeric a-syn), 12 and 8 kDa, which
were absent in all control samples. This is in agreement
with previous studies ﬁnding an increase of both full-length
and dimeric a-syn in the temporal cortex in patients with
DLB compared to controls [43, 45]. These ﬁndings extend
recent reports of reduced level of total a-syn in CSF in
synucleinopathies compared to controls in some [23, 36]
but not all [48] studies, which if conﬁrmed would parallel
the situation in AD with the Aa1–42 peptide [20]. Interest-
ingly, cortical Lewy bodies are absent in the brains of most
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(b) Fig. 4 Individual values for the
ratio (a-syn/total protein) in
biochemically fractionated (Tris
(a), 0.5% Triton
 (b), and SDS
fraction (c)) temporal cortex
Brodmann area 36 (BA36) and
dorsolateral prefrontal cortex
BA9 from controls (grey circle),
patients with dementia with
Lewy bodies (DLB) (black
circle) and Parkinson’s disease
with dementia (PDD) (white
circle) using ELISA
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123normal control individuals [49], which also is consistent
with the observation that negligible amounts of a-syn were
found in the pellets from our control samples. The different
a-syn pattern found in the pellet fractions from brain region
temporal cortex from patients with DLB and PDD com-
pared to controls are also consistent with pathological
changes of a-syn that involves presence of more lipid-
associated oligomeric species and an insoluble fraction of
a-syn species that are not reported in non-diseased brain
tissue [40]. In contrast to temporal cortex BA36, there were
no differences in the content of full-length a-syn in dor-
solateral prefrontal cortex BA9 between controls, patients
with DLB and PDD, and the a-syn bands of 32, 12 and
8 kDa were only present in a few samples. These regional
differences might be explained by previous studies sug-
gesting that the hippocampus, temporal cortex, and inferior
temporal gyrus are particularly vulnerable to Lewy body
formation [50, 51]. Furthermore studies of PD-related
pathology have shown that the dorsolateral prefrontal
cortex is affected considerably later in the disease process
than temporal cortex [50]. This is also consistent with
recent clinical studies suggesting that early impairments in
posteriorly based cognitive functions in PD progress to
dementia, whereas frontally-based impairments is revers-
ible or remains stable [52].
To our knowledge this is the ﬁrst study where intact
a-syn from human brain tissue has been characterized with
mass spectrometry. By using a combination of protein
solubility fractionation, immunoprecipitation and mass
spectrometric top-down sequencing with high resolution
LC–MS/MS we have found at least two novel C-terminally
truncated forms of a-syn, Ac-a-syn1–103 and Ac-a-syn1–139,
and possibly Ac-a-syn1–119. All four identiﬁed forms of
a-syn including the full length a-syn1–140 were found to be
post translationally modiﬁed by N-terminal acetylation.
Hence, we have shown that it is possible by combing tar-
geted antibody based puriﬁcation with solubility fraction-
ation and high resolution proteomics techniques to identify
novel a-syn forms.
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